1. Antonijevic Z. Need for optimal design of pharmaceutical programs and portfolios in modern medical product development. In: Antonijevic Z, ed. Optimization of Pharmaceutical R&D Programs and Portfolios: Design and Investment Strategy. New York: Springer; 2014:3–18.
2. Beckman RA, Clark J, Chen C. Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nature Rev Drug Discov. 2011;10:735–749.
3. Chen C, Beckman RA, Sun LZ. Maximizing return on investment in phase II proof-of-concept trials. In: Antonijevic Z, ed. Optimization of Pharmaceutical R&D Programs and Portfolios: Design and Investment Strategy. New York: Springer; 2014:155–180.
4. Antonijevic Z. Optimization of Pharmaceutical R&D Programs and Portfolios: Design and Investment Strategy. New York: Springer; 2014.
5. Patel NR, Ankolekar S. A Bayesian approach for incorporating economic factors in sample size and design for clinical trials and portfolios of drugs. Stat Med. 2007;26:4976–4988.